Abstract
Introduction
Sickle cell disease causes chronic haemolytic anaemia, dactylitis, and painful acute crises, and increases the risk of stroke, organ damage, bacterial infections, and complications of blood transfusion. In sub-Saharan Africa, up to a third of adults are carriers of the defective sickle cell gene, and 1-2% of babies are born with the disease.
Methods and outcomes
We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of pharmaceutical and non-pharmaceutical interventions to prevent sickle cell crisis and other acute complications in people with sickle cell disease? What are the effects of pharmaceutical and non-pharmaceutical interventions to treat pain in people with sickle cell crisis? We searched: Medline, Embase, The Cochrane Library, and other important databases up to September 2007 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
Results
We found 38 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
Conclusions
In this systematic review we present information relating to the effectiveness and safety of the following interventions: acupuncture, antibiotic prophylaxis in children under 5 years of age, aspirin, avoidance of cold environment, blood transfusion, codeine, corticosteroid (with narcotic analgesics), diflunisal, hydration, hydroxyurea, ibuprofen, ketorolac, limiting physical exercise, malaria chemoprophylaxis, morphine (controlled-release oral after initial intravenous bolus, repeated intravenous doses), oxygen, paracetamol, patient-controlled analgesia, penicillin prophylaxis in children over 5 years of age, piracetam, pneumococcal vaccines, rehydration, and zinc sulphate.
Key Points
In sub-Saharan Africa, up to a third of adults are carriers of the defective sickle cell gene, and 1-2% of babies are born with the disease.
Sickle cell disease causes chronic haemolytic anaemia, dactylitis, and painful acute crises, and increases the risk of stroke, organ damage, bacterial infections, and complications of blood transfusion.
We don’t know whether avoidance of cold environments, physical exercise, or dehydration can prevent crises or complications in people with sickle cell disease.
Penicillin prophylaxis in children under 5 years of age reduces invasive pneumococcal infections regardless of pneumococcal vaccination status. We don’t know whether penicillin prophylaxis is beneficial in older children.
Malaria chemoprophylaxis is considered useful in preventing malaria-induced crises, but we found few studies evaluating its benefit.
Hydroxyurea, piracetam, and zinc sulphate may reduce some complications of sickle cell disease, such as painful crises, compared with placebo, but their long-term effects and safety are unknown.
Morphine is widely used to treat severe pain, but we found no RCT evidence comparing it with placebo in people with sickle cell crises.
Controlled-release oral morphine and patient-controlled analgesia may be as effective as repeated intravenous doses of morphine. Oral morphine increases the risk of acute chest syndrome compared with intravenous administration.
High-dose corticosteroids may reduce the need for analgesia when added to intravenous morphine in people with a sickle cell crisis, but may increase the risks of adverse effects such as infections, hypertension, and metabolic problems.
It is still unclear whether acupuncture, blood transfusion, hydration, oxygen, aspirin, codeine, diflunisal, ibuprofen, ketorolac, or paracetamol reduce pain during sickle cell crisis.
About this condition
Definition
Sickle cell disease refers to a group of disorders caused by inheritance of a pair of abnormal haemoglobin genes, including the sickle cell gene. It is characterised by chronic haemolytic anaemia, dactylitis, and acute episodic clinical events called "crises".Vaso-occlusive (painful) crises are the most common, and because of a resistance to nitric oxide, cause tissue ischaemia. Other crises are acute chest syndrome, sequestration crisis, and aplastic crisis. A common variant of sickle cell disease, also characterised by haemolytic anaemia, occurs in people with one sickle and one thalassaemia gene. Sickle cell trait occurs in people with one sickle gene and one normal gene. People with sickle cell trait have no clinical manifestation of illness. This review covers people with sickle cell disease with or without thalassaemia.
Incidence/ Prevalence
Sickle cell disease is most common in people living in or originating from sub-Saharan Africa. The disorder also affects people of Mediterranean, Caribbean, Middle-Eastern, and Asian origin. The sickle cell gene is most common in areas where malaria is endemic — sickle cell trait affects about 10-30% of Africa’s tropical populations. Sickle cell disease affects an estimated 1-2% (120,000) of infants in Africa annually. About 178 babies (0.28/1000 conceptions) are affected by sickle cell disease in England annually. About 60,000 people in the USA and 10,000 in the UK suffer from the disease.
Aetiology/ Risk factors
Sickle cell disease is inherited as an autosomal recessive disorder. For a baby to be affected, both parents must have the sickle cell gene. In parents with sickle cell trait, the risk of having an affected baby is one in four for each pregnancy. Painful (vaso-occlusive) crisis is the most common feature of the disease, and these episodes start in infancy and early childhood. Factors that precipitate or modulate the occurrence of sickle cell crisis are not fully understood, but infections, hypoxia, dehydration, acidosis, stress (such as major surgery or childbirth), and cold are believed to play some role. In tropical Africa, malaria is the most common cause of anaemic and vaso-occlusive crisis. High levels of fetal haemoglobin are known to ameliorate the severity and incidence of sickle cell crisis and other complications of the disease.
Prognosis
People affected by sickle cell disease are predisposed to bacterial infections, especially those caused by encapsulated organisms such as Pneumococcus, Haemophilus influenzae, Meningococcus, and Salmonella species. Severe bacterial infections such as pneumonia, meningitis, and septicaemia are common causes of morbidity and mortality, especially among young children. About 10% of children with sickle cell anaemia may develop a stroke, and more than 50% of these may suffer recurrent strokes. Abnormal features of cerebral blood vessels shown by transcranial Doppler scan predict a high risk of stroke in children with sickle cell disease. Frequent episodes of crisis, infections, and organ damage reduce the quality of life of people with sickle cell disease. A high rate of vaso-occlusive (painful) crisis is an index of clinical severity that correlates with early death. Life expectancy remains low, especially in communities with poor access to health services. In some parts of Africa, about 50% of children with sickle cell disease die before their first birthday. The average life expectancy with sickle cell disease in the USA is about 42 years for men, and about 48 years for women. Frequent blood transfusions could increase the risk of immune reactions and infections, such as HIV and hepatitis B or C viruses, and Chagas’ disease. The need for repeated blood transfusions in people with sickle cell disease predisposes them to the risk of iron overload.
Aims of intervention
To reduce mortality, the incidence and severity of sickle cell crises, and other acute complications; to prevent organ damage; to improve quality of life and increase life expectancy; to achieve effective pain relief during crises, with minimal adverse effects.
Outcomes
Mortality; dactylitis, incidence of crisis; severity of crisis; incidence of other acute complications (e.g. malaria, stroke, infectious complications [invasive pneumococcal infection or acute osteomyelitis]); quality of life; adverse effects of treatment (e.g. gastrointestinal bleeding owing to NSAIDs, addiction to narcotic analgesics, immune reactions, and infections caused by blood transfusions [e.g. HIV, viral hepatitis, and Chagas’ disease]). Secondary outcomes include duration of crisis, days out of school or work, and requirement for blood transfusion for severe anaemia. Fetal and total haemoglobin levels are considered proxy outcomes and are not addressed in this review.
Methods
Clinical Evidence search and appraisal September 2007. The following databases were used to identify studies for this review: Medline 1966 to September 2007, Embase 1980 to September 2007, and The Cochrane Database of Systematic Reviews 2007, Issue 3. Additional searches were carried out using these websites: NHS Centre for Reviews and Dissemination (CRD) — for all databases, Turning Research into Practice (TRIP), and NICE. Abstracts of the studies retrieved were assessed independently by two information specialists using pre-determined criteria to identify relevant studies. Study design criteria for inclusion in this review were: published systematic reviews and RCTs in any language and containing more than 20 individuals of whom more than 80% were followed up. Open studies were included. For the question on non-pharmaceutical interventions to prevent crisis and acute complications, a minimum length of follow-up of 1 year was required. There was no minimum length of follow-up required to include studies for the other questions. A search for published cohort studies was also undertaken for the avoidance of cold environment and limiting physical exercise interventions, for the question on non-pharmaceutical interventions to prevent crisis and acute complications. In addition, we use a regular surveillance protocol to capture harms alerts from organisations such as the US FDA and the UK Medicines and Healthcare products Regulatory Agency (MHRA), which are continually added to the review as required. We have performed a GRADE evaluation of the quality of evidence for interventions included in this review (see table ). To aid readability of the numerical data in our reviews, we round many percentages to the nearest whole number. Readers should be aware of this when relating percentages to summary statistics such as relative risks (RRs) and odds ratios (ORs).
Table.
GRADE evaluation of interventions for sickle cell disease
| Important outcomes | Incidence of crises, disease-related complications, symptom severity (pain), quality of life, mortality, adverse effects | ||||||||
| Number of studies (participants) | Outcome | Comparison | Type of evidence | Quality | Consistency | Directness | Effect size | GRADE | Comment |
| What are the effects of non-pharmaceutical interventions to prevent sickle cell crisis and other acute complications in people with sickle cell disease? | |||||||||
| 2 (209) | Disease-related complications | Blood transfusion (prophylactic) v standard care or no treatment | 4 | 0 | 0 | 0 | +1 | High | Effect-size point added for OR less than 0.5 |
| 2 (209) | Mortality | Blood transfusion (prophylactic) v standard care or no treatment | 4 | 0 | 0 | 0 | 0 | High | |
| What are the effects of pharmaceutical interventions to prevent sickle cell crisis and other acute complications in people with sickle cell disease? | |||||||||
| 2 (457) | Disease-related complications | Penicillin v placebo (children under 5 years of age) | 4 | 0 | 0 | –1 | +1 | High | Directness point deducted for differences in vaccination status of children. Effect size point added for RR less than 0.5 |
| 2 (215) | Mortality | Penicillin v placebo (children under 5 years of age) | 4 | –1 | 0 | 0 | 0 | Moderate | Quality point deducted for low event rates |
| 1 (400) | Disease-related complications | Penicillin v placebo (children over 5 years of age) | 4 | –1 | 0 | 0 | 0 | Moderate | Quality point deducted for incomplete reporting of results |
| 2 (215) | Mortality | Penicillin v placebo (children under 5 years of age) | 4 | –1 | 0 | 0 | 0 | Moderate | Quality point deducted for incomplete reporting of results |
| 1 (299) | Incidence of crises | Hydroxyurea v placebo | 4 | 0 | 0 | 0 | 0 | High | |
| 1 (299) | Disease-related complications | Hydroxyurea v placebo | 4 | –1 | 0 | 0 | 0 | Moderate | Quality point deducted for incomplete reporting of results |
| 1 (299) | Mortality | Hydroxyurea v placebo | 4 | –1 | 0 | 0 | 0 | Moderate | Quality point deducted for incomplete reporting of results |
| 1 (299) | Quality of life | Hydroxyurea v placebo | 4 | –1 | 0 | 0 | 0 | Moderate | Quality point deducted for incomplete reporting of results |
| 1 (97) | Incidence of crises | Malaria chemoprophylaxis v placebo | 4 | –1 | 0 | –1 | +1 | Moderate | Quality point deducted for sparse data. Directness point deducted for uncertainty about generalisability of regimens used for prophylaxis. Effect size point added for RR less than 0.5 |
| 1 (97) | Disease-related complications | Malaria chemoprophylaxis v placebo | 4 | –1 | 0 | 0 | 0 | Moderate | Quality point deducted for sparse data |
| 1 (157) | Disease-related complications | Malaria chemoprophylaxis plus antibiotic v placebo | 4 | –2 | 0 | –1 | 0 | Very low | Quality points deducted for sparse data and randomisation/allocation flaws. Consistency point deducted for conflicting results. Directness point deducted for uncertainty about generalisability of regimens used for prophylaxis |
| 3 (169) | Incidence of crises | Piracetam v placebo | 4 | –2 | –1 | 0 | 0 | Very low | Quality points deducted for sparse data and incomplete reporting of results. Consistency point deducted for lack of agreement between studies |
| 1 (145) | Incidence of crises | Zinc sulphate v placebo | 4 | –1 | 0 | –1 | 0 | Low | Quality point deducted for sparse data. Directness point deducted for uncertainty about results because of small size of RCT |
| 1 (242) | Disease-related complications | Polysaccharide pneumococcal vaccine v control | 4 | 0 | 0 | 0 | 0 | High | |
| What are the effects of non-pharmaceutical interventions to treat pain in people with sickle cell crisis? | |||||||||
| 1 (50) | Symptom severity (pain) | Oxygen v air | 4 | –2 | 0 | 0 | 0 | Low | Quality points deducted for sparse data and incomplete reporting of results |
| What are the effects of pharmaceutical interventions to treat pain in people with sickle cell crisis? | |||||||||
| 1 (20) | Symptom severity (pain) | Patient-controlled pethidine v intermittently administered pethidine | 4 | –2 | 0 | 0 | 0 | Low | Quality points deducted for sparse data and uncertainty about method of evaluating pain |
| 1 (45) | Symptom severity (pain) | Patient-controlled morphine v intermittently administered morphine | 4 | –1 | 0 | 0 | 0 | Moderate | Quality point deducted for sparse data |
| 1 (37) | Symptom severity (pain) | Diflunisal v placebo | 4 | –3 | 0 | 0 | 0 | Very low | Quality points deducted for sparse data, incomplete reporting of results, and randomisation/allocation flaws |
| 1 (20) | Symptom severity (pain) | Ketorolac v pethidine | 4 | –2 | –1 | 0 | 0 | Very low | Quality points deducted for sparse data and randomisation/allocation flaws. Consistency point deducted for different results at different endpoints |
| 2 (39) | Symptom severity (pain) | Ketorolac plus pethidine v placebo plus pethidine | 4 | –2 | –1 | 0 | 0 | Very low | Quality points deducted for sparse data and randomisation/allocation flaws. Consistency point deducted for assessing different outcomes and for lack of agreement between studies |
| 1 (29) | Symptom severity (pain) | Ketorolac plus morphine sulphate v placebo plus morphine sulphate | 4 | –2 | 0 | 0 | 0 | Low | Quality points deducted for sparse data and randomisation/allocation flaws |
| 2 (114) | Symptom severity (pain) | Dexamethasone plus morphine v placebo | 4 | –2 | 0 | –1 | 0 | Very low | Quality points deducted for sparse data and randomisation/allocation flaws. Directness point deducted for not assessing pain reduction |
| 1 (34) | Symptom severity (pain) | Methylprednisolone plus morphine v placebo | 4 | –2 | 0 | 0 | 0 | Low | Quality points deducted for sparse data and randomisation/allocation flaws |
| 1 (86) | Symptom severity (pain) | Oral morphine v intravenous morphine | 4 | –1 | 0 | 0 | 0 | Moderate | Quality point deducted for sparse data |
Type of evidence: 4 = RCT; 2 = Observational; Consistency: similarity of results across studies Directness: generalisability of population or outcomes Effect size: based on relative risk or odds ratio
Glossary
- Acute chest syndrome
Acute chest syndrome is a life-threatening complication of sickle cell disease characterised by fever, cough, chest pain, difficulty in breathing, worsening anaemia, and new pulmonary infiltrates on radiography. It is difficult to differentiate acute chest syndrome clinically from pneumonia and pulmonary infarctions.
- Aplastic crisis
Sudden cessation of the bone marrow from making new blood cells.
- CHEOPS scale (Children's Hospital of Eastern Ontario Pain scale)
A behavioural scale used to evaluate postoperative pain. It was initially validated in children aged 1–5 years, and subsequently validated in children from other populations and ages. The CHEOPS scale is used to monitor the effectiveness of interventions for reducing pain and discomfort. Scores obtained from adding points from six different parameters range from 4 to 13.
- Dactylitis
Inflammation of the bones of the hands and feet, resulting in swelling, redness, and pain in the affected parts. It is common in young infants with sickle cell disease, and is precipitated by the sickle process that characterises sickle cell disease. Because it tends to occur bilaterally in the hands and feet with swelling of the dorsum, it is commonly described as sickle cell “hand and foot syndrome”.
- Fetal haemoglobin (Hb F)
This is the predominant type of normal haemoglobin (i.e. the oxygen carrying molecule in the human red blood cell) in the unborn child. Following birth, another type of normal haemoglobin (Hb A) replaces Hb F and remains predominant throughout life. Hb F binds oxygen more strongly than Hb A and maintains higher tissue oxygen tension than Hb A.
- High-quality evidence
Further research is very unlikely to change our confidence in the estimate of effect.
- Low-quality evidence
Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
- Moderate-quality evidence
Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
- Pneumococcal conjugate vaccines
These are polysaccharide pneumococcal vaccines linked with proteins such as those of the outer membrane of meningococcus, or tetanus, or diphtheria toxoids. The conjugate pneumococcal vaccines have been shown to be immunogenic in children younger than 2 years, and are recommended for routine use in infants beginning from the age of 2 months.
- Polyvalent polysaccharide pneumococcal vaccine (PPV)
This type of vaccine contains the purified capsular polysaccharides of several Streptococcus pneumoniae serotypes. Many of the polysaccharides contained in the vaccines do not induce protective immunity in children younger than 2 years. This type of pneumococcal vaccine is recommended for children aged 2 years and older affected by conditions that predispose them to an increased risk of invasive pneumococcal infection.
- Sequestration crisis
Sudden pooling of blood in the spleen and liver, with the result that the person becomes anaemic and hypotensive, with the affected organ becoming remarkably enlarged and painful.
- Very low-quality evidence
Any estimate of effect is very uncertain.
NSAIDs
Disclaimer
The information contained in this publication is intended for medical professionals. Categories presented in Clinical Evidence indicate a judgement about the strength of the evidence available to our contributors prior to publication and the relevant importance of benefit and harms. We rely on our contributors to confirm the accuracy of the information presented and to adhere to describe accepted practices. Readers should be aware that professionals in the field may have different opinions. Because of this and regular advances in medical research we strongly recommend that readers' independently verify specified treatments and drugs including manufacturers' guidance. Also, the categories do not indicate whether a particular treatment is generally appropriate or whether it is suitable for a particular individual. Ultimately it is the readers' responsibility to make their own professional judgements, so to appropriately advise and treat their patients.To the fullest extent permitted by law, BMJ Publishing Group Limited and its editors are not responsible for any losses, injury or damage caused to any person or property (including under contract, by negligence, products liability or otherwise) whether they be direct or indirect, special, incidental or consequential, resulting from the application of the information in this publication.
References
- 1.Akinyanju OO. A profile of sickle cell disease in Nigeria. Ann N Y Acad Sci 1989;565:126–136. [DOI] [PubMed] [Google Scholar]
- 2.Serjeant GR. Sickle cell disease, 2nd rev ed. Oxford: Oxford University Press, 1992. [Google Scholar]
- 3.Ohene-Frempong K, Nkrumah FK. Sickle cell disease in Africa. In: Embury SH, Hebbel RP, Mohandas N, et al, eds. Sickle cell disease: basic principles and clinical practice. New York: Raven Press Ltd, 1994. [Google Scholar]
- 4.Hickman M, Modell B, Greengross P, et al. Mapping the prevalence of sickle cell and beta thalassaemia in England: estimating and validating ethnic-specific rates. Br J Haematol 1999;104:860–867. [DOI] [PubMed] [Google Scholar]
- 5.Davies SC, Oni L. Management of patients with sickle cell disease. BMJ 1997;315:656–660. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Effiong CE. Sickle cell disease in childhood. In: Fleming AF, ed. Sickle cell disease: a handbook for general clinicians. Edinburgh: Churchill Livingstone, 1982:57–72. [Google Scholar]
- 7.Overturf GD, Powars D, Baraff LJ. Bacterial meningitis and septicemia in sickle cell disease. Am J Dis Child 1977;131:784–787. [DOI] [PubMed] [Google Scholar]
- 8.Cohen AR, Norris CF, Smith-Whitley K. Transfusion therapy for sickle cell disease. In: Capon SM, Chambers LA, eds. New directions in pediatric hematology. Bethesda, MD: American Association of Blood Banks, 1996:39–85. [Google Scholar]
- 9.Adams R, McKie V, Nichols F, et al. The use of transcranial ultrasonography to predict stroke in sickle cell disease. N Engl J Med 1992;326:605–610. [DOI] [PubMed] [Google Scholar]
- 10.Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med 1994;330:1639–1643. [DOI] [PubMed] [Google Scholar]
- 11.Harmatz P, Butensky E, Quirolo K, et al. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 2000;96:76–79. [PubMed] [Google Scholar]
- 12.Redwood AM, Williams EM, Desal P, et al. Climate and painful crisis of sickle-cell disease in Jamaica. BMJ 1976;1:66–68. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Mohan J, Marshall JM, Reid HL, et al. Peripheral vascular response to mild indirect cooling in patients with homozygous sickle cell (SS) disease and the frequency of painful crisis. Clin Sci 1998;94:111–120. [DOI] [PubMed] [Google Scholar]
- 14.Saborio P, Scheinman JI. Sickle cell nephropathy. J Am Soc Nephrol 1999;10:187–192. [DOI] [PubMed] [Google Scholar]
- 15.Riddington C, Wang WC. Blood transfusion for preventing stroke in people with sickle cell disease. In: The Cochrane Library, Issue 1, 2002. Chichester, UK: John Wiley & Sons Ltd. Search date 2006. [DOI] [PubMed] [Google Scholar]
- 16.Adams RJ, McKie VC, Brambilla D, et al. Stroke prevention trial in sickle cell anemia. Control Clin Trials 1998;19:110–129. [DOI] [PubMed] [Google Scholar]
- 17.Adams RJ, Brambilla D, Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 2005;353:2769–2778. [DOI] [PubMed] [Google Scholar]
- 18.Hirst C, Owusu-Ofori S. Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. In: The Cochrane Library, Issue 3, 2006. Chichester, UK: John Wiley & Sons Ltd. Search date 2005; primary sources Cochrane Cystic Fibrosis and Genetic Disorders Group Haemoglobinopathies Trials Register, references identified from comprehensive electronic database searches, and hand searches of relevant journals and abstract books of conference proceedings. [Google Scholar]
- 19.Overturf GD. Pneumococcal vaccination of children. Semin Pediatr Infect Dis 2002;13:155–164. [DOI] [PubMed] [Google Scholar]
- 20.Falletta JM, Woods GM, Verter JI, et al. Discontinuing penicillin prophylaxis in children with sickle cell anemia. J Pediatr 1995;127:685–690. [DOI] [PubMed] [Google Scholar]
- 21.Davies S, Olujohungbe A. Hydroxyurea for sickle cell disease. In: The Cochrane Library, Issue 3, 2006. Chichester, UK: John Wiley & Sons Ltd. Search date 2004. [Google Scholar]
- 22.Ferster A, Vermylen C, Cornu G, et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood 1996;88:1960–1964. [PubMed] [Google Scholar]
- 23.Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. N Engl J Med 1995;332:1317–1322. [DOI] [PubMed] [Google Scholar]
- 24.Oniyangi O, Omari AAA. Malaria chemoprophylaxis in sickle cell disease. In: The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons Ltd. Search date 2006; primary sources Cochrane Infectious Diseases Group Specialized Register, Cochrane Cystic Fibrosis and Genetic Disorders Group Specialized Register, Central (The Cochrane Library), Medline, Embase, Liliacs, and reference lists. [Google Scholar]
- 25.Al Hajeri A, Fedorowicz Z, Omran A, et al. Piracetam for reducing the incidence of painful sickle cell disease crises. In: The Cochrane Library, Issue 2, 2007. Chichester, UK: John Wiley & Sons, Ltd. Search date 2007; primary sources Cochrane Cystic Fibrosis and Genetic Disorders Group Haemoglobinopathies Trials Register which comprises of references identified from comprehensive electronic database searches and hand searches of relevant journals and abstract books of conference proceedings. 17443614 [Google Scholar]
- 26.Mikati MA, Solh HM, Deryan DE, et al. A preliminary report on piracetam in sickle cell anemia: a double-blind crossover clinical trial and effects on erythrocyte survival. King Faisal Spec Hosp Med J 1983;3:233–236. [Google Scholar]
- 27.Singh PC, Ballas SK. Drugs for preventing red blood cell dehydration in people with sickle cell disease. In: The Cochrane Library, Issue 4, 2007. Chichester, UK: John Wiley & Sons Ltd. Search date 2006. [DOI] [PubMed] [Google Scholar]
- 28.Davies EG, Riddington C, Lottenberg R, et al. Pneumococcal vaccines for sickle cell disease. In: The Cochrane Library, Issue 3, 2006. Chichester, UK: John Wiley & Sons Ltd. Search date 2004; primary sources Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register, references identified from comprehensive electronic database searches, hand searches of relevant journals and abstract books of conference proceedings, and contact with relevant pharmaceutical companies and experts in the field. [Google Scholar]
- 29.Pai VB, Heyman CA, Erramouspe J, et al. Conjugated heptavalent pneumococcal vaccine. Ann Pharmacother 2002;36:1403–1413. [DOI] [PubMed] [Google Scholar]
- 30.Okomo U, Meremikwu MM. Fluid replacement therapy for acute episodes of pain in people with sickle cell disease. In: The Cochrane Library, Issue 2, 2007. Chichester, UK: John Wiley & Sons Ltd. Search date 2007; primary sources Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register, which comprises of references identified from comprehensive electronic database searches and hand searches of relevant journals and abstract books of conference proceedings. 17443589 [Google Scholar]
- 31.Robieux IC, Kellner JD, Coppes MJ, et al. Analgesia in children with sickle cell crisis: comparison of intermittent opioids vs. continuous intravenous infusion of morphine and placebo-controlled study of oxygen inhalation. Pediatr Hematol Oncol 1992;9:317–326. [DOI] [PubMed] [Google Scholar]
- 32.Zipursky A, Robieux IC, Brown EJ, et al. Oxygen therapy in sickle cell disease. Am J Pediatr Hematol Oncol 1992;14:222–228. [DOI] [PubMed] [Google Scholar]
- 33.Hirst C, Williamson L. Preoperative blood transfusions for sickle cell disease. In: The Cochrane Library, Issue 3, 2007. Chichester, UK: John Wiley & Sons Ltd. Search date 2007; primary sources Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises references identified from comprehensive electronic database searches, hand searches of relevant journals and abstract books of conference proceedings. [Google Scholar]
- 34.Telen MJ. Principles and problems of transfusion in sickle cell disease. Semin Hematol 2001;38:315–323. [DOI] [PubMed] [Google Scholar]
- 35.Hirst C, Wang WC. Blood transfusion for preventing stroke in people with sickle cell disease. In: The Cochrane Library, Issue 3, 2007. Chichester, UK: John Wiley & Sons Ltd. Search date 2006; primary sources Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register, comprising references identified from comprehensive electronic database searches and hand searches of relevant journals and conference proceedings. [Google Scholar]
- 36.Emre U, Miller ST, Gtierez M, et al. Effect of transfusion in acute chest syndrome of sickle cell disease. J Pediatr 1995;127:901–904. [DOI] [PubMed] [Google Scholar]
- 37.Talano JM, Hillery CA, Gottschall JL, et al. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. Pediatrics 2003;111:e661–e665. [DOI] [PubMed] [Google Scholar]
- 38.Perlin E, Finke H, Castro O, et al. Infusional/patient-controlled analgesia in sickle-cell vaso-occlusive crises. Pain Clinic 1993;6:113–119. [Google Scholar]
- 39.Gonzalez ER, Bahal N, Hansen LA, et al. Intermittent injection vs patient-controlled analgesia for sickle cell crises pain: comparison in patients in the emergency department. Arch Intern Med 1991;151:1373–1378. [PubMed] [Google Scholar]
- 40.Hagmeyer KO, Mauro LS, Mauro VF. Meperidine-related seizures associated with patient-controlled analgesia pumps. Ann Pharmacother 1993;27:29–33. [DOI] [PubMed] [Google Scholar]
- 41.Shapiro BS, Ballas SK. The acute painful episode. In: Embury SH, Hebbel RP, Mohandas N, et al, eds. Sickle cell disease: principles and clinical practice. New York: Raven Press Ltd, 1994. [Google Scholar]
- 42.Dunlop RJ, Bennett KC. Pain management for sickle cell disease. In: The Cochrane Library, Issue 2, 2006. Chichester, UK: John Wiley & Sons Ltd. Search date 2002. 16625580 [Google Scholar]
- 43.Perlin E, Finke H, Castro O, et al. Treatment of sickle cell pain crisis: a clinical trial of diflunisal (Dolobid). Clin Trials J 1988;25:254–264. [Google Scholar]
- 44.Grisham JE, Vichinsky EP. Ketorolac versus meperidine in vaso-occlusive crisis: a study of safety and efficacy. Int J Pediatr Hematol Oncol 1996;3:239–247. [Google Scholar]
- 45.Wright SW, Norris RL, Mitchell TR. Ketorolac for sickle cell vaso-occlusive crisis pain in the emergency department: lack of a narcotic-sparing effect. Ann Emerg Med 1992;21:925–928. [DOI] [PubMed] [Google Scholar]
- 46.Perlin E, Finke H, Castro O, et al. Enhancement of pain control with ketorolac tromethamine in patients with sickle cell vaso-occlusive crisis. Am J Hematol 1994;46:43–47. [DOI] [PubMed] [Google Scholar]
- 47.Hardwick WE, Givens TG, Monroe KW, et al. Effect of ketorolac in pediatric sickle cell vaso-occlusive pain crisis. Pediatr Emerg Care 1999;15:179–182. [DOI] [PubMed] [Google Scholar]
- 48.Bernini JC, Rogers ZR, Sandler ES, et al. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood 1998;92:3082–3089. [PubMed] [Google Scholar]
- 49.Rogers ZR, Dale JC, Bernini JC, et al. Dexamethasone shortens the duration of painful events requiring hospitalisation in children with sickle cell disease: results of a randomized double-blind placebo-controlled trial. Blood 1995;86:250a. [Google Scholar]
- 50.Griffin TC, McIntire D, Buchanan GR. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med 1994;330:733–737. [DOI] [PubMed] [Google Scholar]
- 51.Jacobson SJ, Kopecky EA, Joshi P, et al. Randomised trial of oral morphine for painful episodes of sickle-cell disease in children. Lancet 1997;350:1358–1361. [DOI] [PubMed] [Google Scholar]
- 52.Kopecky EA, Jacobson S, Joshi P, et al. Systematic exposure to morphine and the risk of acute chest syndrome in sickle cell disease. Clin Pharmacol Ther 2004;75:140–146. [DOI] [PubMed] [Google Scholar]
- 53.Overturf GD. American Academy of Pediatrics. Technical report: prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis. Pediatrics 2000;106:367–376. [DOI] [PubMed] [Google Scholar]
- 54.Suraseranivongse S, Santawat U, Kraiprasit K, et al. Cross-validation of a composite pain scale for preschool children within 24 hours of surgery. Br J Anaesth 2001;87:400–405. [DOI] [PubMed] [Google Scholar]